Renoprotective effects of dulaglutide in patients with T2DM and CKD

Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

4 Citationer (Scopus)

Abstract

The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.

OriginalsprogEngelsk
TidsskriftNature Reviews. Nephrology
Vol/bind14
Udgave nummer11
Sider (fra-til)659-660
ISSN1759-5061
DOI
StatusUdgivet - 2018

Citationsformater